Mavacamten is a pharmaceutical raw material that functions as a cardiac myosin inhibitor. It is used in the manufacturing of treatments for symptomatic obstructive hypertrophic cardiomyopathy.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1642288-47-8
Razpipadon
pharmaceutical raw material
Norglipin
pharmaceutical raw material
(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylsulfinyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
pharmaceutical raw material
Iptacopan
pharmaceutical raw material
6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
RLCLASQCAPXVLM-NSHDSACASA-N
C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C